SMYD3 and small cell lung carcinoma: To further test the relevance of SMYD3–RNF113A signaling, we then took advantage of the SCLC cell line DMS-114, originating from a chemotherapy-naïve patient with relatively low expression of RNF113A and SMYD3 compared with other SCLC cell lines (see Fig. 3C).